"We demonstrate that patients with metastatic disease stayed on therapy longer—a median of 9 months vs 7 months for the non-metastatic patients," says Rana R. McKay, MD, FASCO. Overall, data from the ...

UroLift patients demonstrated superior recovery outcomes, including higher satisfaction and improved sexual function, compared to Rezūm patients. The study showed significant differences in ...

"We see the overall survival, whether it is [in] all-comers, in HRR gene mutation-positive patients, or in HRR gene [mutation]-negative patients or [those] who did not have mutations, the overall ...

"We have communicated with Solventum, who makes this software, and they have made changes based on our feedback," says Timothy D. Lyon, MD. Investigators recently identified key concerns in the US ...

Pembrolizumab and lenvatinib showed clinical activity in locally advanced, non-metastatic clear cell RCC, with a median tumor reduction of 22%. The combination had a manageable safety profile, with ...

ProACT is recommended for non-radiated patients with stress urinary incontinence, offering adjustability for mild to severe cases. The procedure combines cystoscopy and fluoroscopy, with postoperative ...

Experts discuss how they communicate various treatment options for non–muscle-invasive bladder cancer (NMIBC) with patients and health care professionals.

FG-3246 demonstrated promising clinical activity and manageable safety in a phase 1 trial for mCRPC, with a maximum tolerated dose of 2.7 mg/kg every three weeks. Notable adverse events included ...

Experts share their initial impressions of the available data on immunotherapies, including PD-L1 inhibitors durvalumab and sasanlimab, being evaluated in bacille Calmette-Guérin (BCG)–unresponsive ...

"We must lobby to maintain our current funding levels and push for increased support to continue driving progress in cancer care," says Michael S. Cookson, MD, MMHC, FACS. “Healthy citizens are the ...

“If it is as efficacious as it looks, we will have more patients who are getting effective standard of care treatment, not needing to go on to further treatment, not having recurrences, [having ...

High interreader and intrareader agreement rates were found, especially in newly diagnosed prostate cancer patients, supporting 18F-Flotufolastat's FDA approval. Lower agreement rates in the ...